Recommended Reading

Saniona has announced positive top-line results from the Phase 2 open-label extension study of Tesomet in patients with hypothalamic obesity (HO).

Lipocalin-2 (LCN2) hormone could be used as a potential treatment in people with obesity whose natural signals for feeling full no longer work, after researchers found that it can suppress food intake and increase the feeling of fullness in mice and has shown similar results in